Electrotherapy Treatment For Chronic Pain Emerges During COVID-19 Pandemic To Avoid Opioid Addiction; Bioelectronics Fusion Of Device Technology And Medicine Developed By Firms Such As Electromedical Technologies, Inc. (OTCQB: EMED) And MedTronic PLC

During the COVID-19 pandemic and the worsening opioid addiction crisis, bioelectronics is offering an alternative treatment for chronic and acute pain. Treating post-surgical and other patients suffering from chronic and acute pain, companies like Electromedical Technologies, Inc. (OTCQB: EMED) And MedTronic PLC (NYSE: MDT) are offering more device technology to offer bioelectronics. EMED is also collaborating with more universities and colleges to R&D and certify therapists in this field to raise the profile of bioelectronics and its available non-opioid treatments.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

Electrotherapy Treatment For Chronic Pain Emerges During COVID-19 Pandemic And Avoids Opioid Addiction; Bioelectronics Fusion Of Device Technology And Medicine Is Developed By Firms Such As Electromedical Technologies, Inc. (OTCQB: EMED) And MedTronic PLC (NYSE: MDT)

Yousef Al-Abed, PhD and Director of the Feinstein Institutes for Medical Research at Northwell Health(R), said bioelectric medicine is a new approach to diagnosing and treating disease and injury. "It represents a convergence of molecular medicine, neuroscience and bioengineering. Bioelectronic medicine uses device technology to read and modulate the electrical activity within the body's nervous system, opening new doors to real-time diagnostics and treatment options for patients."

Electromedical Technologies, Inc. (OTCQB: EMED) Establishes New Certification Training Program With School

As a leader in the future of medicine, Electromedical Technologies, Inc. (OTCQB: EMED) announced yesterday (November 4, 2020) that it had reached agreement to collaborate with the Energetic Wellness School of Naturopathy, located in Oklahoma, to develop a new distribution platform and certification training program for "Bioelectronics Therapist and Master Device Technician." The certification program and curriculum are pending approval, the School said. Electrotherapy Treatment For Chronic Pain Emerges During COVID-19 Pandemic And Avoids Opioid Addiction; Bioelectronics Fusion Of Device Technology And Medicine Is Developed By Firms Such As Electromedical Technologies, Inc. (OTCQB: EMED) And MedTronic PLC (NYSE: MDT).

Matthew Wolfson, founder and CEO of Electromedical Technologies, Inc. (OTCQB: EMED), said, "Doctors and students will have access to the Wellness Pro(R) Plus devices, which will give them a hands on understanding of the various techniques and benefits of using drug free application techniques for chronic, acute post traumatic and intractable pain."

Dr. Lee Woolley, DNM, GNM, MBnC, noted, "We cannot wait for the company to release its new wearable Wellness Pro(R) Pod next year. This will be a game changer for practitioners and patients dealing with chronic pain, because it gives that ability for the Doctors to provide their patients with safer choice and send the patient home with a POD rather than a bottle of Opioids." Electrotherapy Treatment For Chronic Pain Emerges During COVID-19 Pandemic And Avoids Opioid Addiction; Bioelectronics Fusion Of Device Technology And Medicine Is Developed By Firms Such As Electromedical Technologies, Inc. (OTCQB: EMED) And MedTronic PLC (NYSE: MDT).

Electromedical Technologies, Inc. (OTCQB: EMED) Planning Wellness Pro(R) Pod.

As chronic and acute pain is made worse by the COVID-19 pandemic, medical company leaders are developing new solutions and preparing to launch new devices. Electromedical Technologies, Inc. (OTCQB: EMED) is a commercial stage company marketing a line of FDA cleared devices for the treatment of chronic acute post traumatic and post-operative, intractable pain relief. Its WellnessPro(TM)Plus device treats chronic and acute pain. The Company is planning to launch another device, the Wellness Pro(R) Pod. It is collaborating with universities and colleges to establish a comprehensive research program that defines the effects of electro-modulation on the human body -- especially cell signaling and its effects on virus assembly and immune responses.

MedTronic PLC (NYSE: MDT) has developed a drug infusion systems for chronic pain including its PTM(TM) Personal Therapy Manager works with the SynchroMed(TM) II Pump to help alleviate unpredictable pain by enabling on-demand intrathecal boluses. It is designed to help eliminate the need to treat unpredictable pain with systematic medication.

Chronic Pain Treatment Market Projected To Reach $151.7 Billion By 2030

Research firm Prescient & Strategic Intelligence sees the chronic pain treatment market hitting $151.7 Billion by 2030, reflecting a CAGR of 6.5%% during the forecast period from 2020-2030. The pandemic accelerated the opioid epidemic crisis in the research period. The report finds that North America dominates the global chronic pain market.

Source: Stock Market Press

Join Stock Market Press' newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:

Statements in this news release may be "forward-looking statements." Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

comtex tracking

COMTEX_373992076/2718/2020-11-05T09:35:49

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.